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ABSTRACT 
 
Background and Purpose: Automated measurements of ECG intervals by current generation 
digital electrocardiographs are critical to computer-based ECG diagnostic statements, to serial 
comparison of ECGs, and to epidemiological studies of ECG findings in populations.  A previous 
study demonstrated generally small but often significant systematic differences among four 
algorithms widely used for automated ECG in the United States, and that measurement 
differences could be related to the degree of abnormality of the underlying tracing.  Since that 
publication, some algorithms have been adjusted, while other large manufacturers of automated 
ECGs have asked to participate in an extension of this comparison.   
Methods: Seven widely used automated algorithms for computer-based interpretation 
participated in this blinded study of 800 digitized ECGs provided by the Cardiac Safety 
Research Consortium (CSRC).  All tracings were different from the study of four algorithms 
reported in 2014, and the selected population was heavily weighted toward groups with known 
effects on the QT interval: included were 200 normal subjects, 200 normal subjects receiving 
moxifloxacin as part of an active control arm of thorough QT studies, 200 subjects with 
genetically proved long QT syndrome Type 1 (LQT1), and 200 subjects with genetically proved 
long QT syndrome Type 2 (LQT2).   
Results: For the entire population of 800 subjects, pairwise differences between algorithms for 
each mean interval value were clinically small, even where statistically significant, ranging from 
0.2 to 3.6 ms for the PR interval, 0.1 to 8.1 ms for QRS duration, and 0.1 to 9.3 ms for QT 
interval. The mean value of all paired differences among algorithms was higher in the long QT 
groups than in normals for both QRS duration and QT intervals.  Differences in mean QRS 
duration ranged from 0.2 to 13.3 ms in the LQT1 subjects and from 0.2 to 11.0 ms in the LQT2 
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subjects.  Differences in measured QT duration (not corrected for heart rate) ranged from 0.2 to 
10.5 ms in the LQT1 subjects and from 0.9 to 12.8 ms in the LQT2 subjects.     
Conclusions: Among current generation computer-based electrocardiographs, clinically small 
but statistically significant differences exist between ECG interval measurements by individual 
algorithms. Measurement differences between algorithms for QRS duration and for QT interval 
are larger in long QT interval subjects than in normal subjects.  Comparisons of population 
study norms should be aware of small systematic differences in interval measurements due to 
different algorithm methodologies, within-individual interval measurement comparisons should 
use comparable methods, and further attempts to harmonize interval measurement 
methodologies are warranted. 
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INTRODUCTION 
Measurements of intervals and durations are critical to clinical diagnoses made by 
automated ECG algorithms.1, 2 Because some ECG measurement points, such as the end of the 
T wave and the end of the QRS complex, have no precise medical definition, individual 
algorithm manufacturers have evolved different engineering solutions to this problem. As a 
consequence, different automated algorithms may produce different measurements of the same 
underlying ECG waveform.3-5 Even where measurement differences are small, systematic 
differences might have consequences for automated ECG interpretation that is based on 
discrete interval partitions, including serial studies of drug effects on the QT interval.5-8  Further, 
unrecognized systematic differences might confound measurement-based comparisons of 
normal values from epidemiological studies that might otherwise use different algorithms from 
different electrocardiographs.9-11  A recent study found small differences in ECG interval 
measurements among 4 major algorithms that are currently widely used in the United States.3  
Since then, some modifications to measurement algorithms were undertaken by study 
participants. In conjunction with the study results and availability of additional ECGs, other 
manufacturers asked that the original study be expanded.  Accordingly, we examined 
differences in automated ECG intervals measured by current generation digital 
electrocardiographs from seven different manufacturers in a new database from the Cardiac 
Safety Research Consortium (CSRC) 12, 13 comprising normal subjects, subjects on 
moxifloxacin, and two expanded subgroups of subjects with genetically documented variants of 
long QT syndrome.14, 15  Our goal was to document whatever systematic differences might 
currently exist among widely used automated ECG measurement algorithms, and to re-examine 
the hypothesis that the magnitude of interval measurement differences among algorithms is 
dependent on the degree of abnormality of the selected ECGs. 
METHODS 
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Participants 
 Seven manufacturers of computerized ECG analysis programs that are widely used 
around the world in automated electrocardiographs agreed to participate in the present study, 
which was performed during a supervised session at the 2016 annual meeting of the 
International Society for Computerized Electrocardiography (ISCE) in Tucson, AZ, USA.  
Included in the study as participants are AMPS-LLC (New York, NY, USA), GE Healthcare 
(Milwaukee, WI, USA), The Glasgow Program, University of Glasgow (Glasgow, Scotland, UK), 
The MEANS Program, Erasmus University Medical Center (Rotterdam, The Netherlands), 
Mortara Instrument (Milwaukee, WI, USA), Philips Healthcare (Andover, MA, USA) and Schiller 
AG (Baar, Switzerland). No extramural funding was used to support this work. The authors are 
solely responsible for the design and conduct of this study, all study analyses, the drafting and 
editing of the final paper and its final contents. 
Population and automated measurements 
The ECG dataset provided by the Cardiac Safety Research Consortium (CSRC) 12, 13 for 
the present study is completely different from the digitized tracings used in the 2014 study.3  The 
ECGs were randomly selected from available ECGs within the CSRC data warehouse by the 
study statistician (CG) while maintaining balance across sex when possible.  All ECGs in the 
present dataset were reviewed by a single investigator (PK) to eliminate tracings with excessive 
noise and also rhythms with no identifiable P wave.  Participants agreed to publication of the 
results in advance of analysis.  All measurement data were simultaneously acquired by 
participants on randomly sequenced media, and the results were immediately given to CSRC 
for analysis during the supervised analysis period.  Measurements of the RR interval, PR 
interval, QRS duration, and QT interval were made blindly by each of the seven algorithms from 
800 XML files of 500 Hz ECG tracings stored in the US FDA ECG Warehouse. 13  Because all 
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measurements for each algorithm were performed from previous XML conversion of digitized 
data, there is no variability of repeated measurements within single algorithms such as might 
have occurred with sequential analysis of analog to digital data conversions.  QT intervals 
presented are the absolute measurements, not corrected for heart rate. 
Included were four groups selected by CSRC according to expected QT interval and 
degree of repolarization abnormality, comprising 200 10-second 12-lead ECGs from each of (1) 
normal subjects during placebo or baseline study period from thorough QT (TQT) studies, (2) a 
separate group of normal subjects during peak moxifloxacin effect during TQT studies, (3) 
subjects with genotyped congenital long QT syndrome (LQTS) Type 1, and (4) subjects with 
genotyped LQTS Type 2.14, 15  Other primary and secondary repolarization changes, as well as 
other causes of atrioventricular and intraventricular block, are also important but extend beyond 
the scope possible in this report.  Since the purpose of the study was to assess and to quantify 
potential differences among algorithms, no human over-reading and no “gold standard” for 
accuracy of the reported measurements were used.  Within each of the normal and moxifloxacin 
groups, the sex distribution was balanced (100 men and 100 women per group); however, of the 
200 subjects within the LQT1 and LQT2 groups, there were 78 men and 122 women and 99 
men and 101 women, respectively.  Inequality of sex distribution was necessary in the LQT 
groups to keep all ECG data digitized at 500 samples/sec rather than the lower high frequency 
cutoff in older tracings. The mean age was similar in all groups, ranging from 29 to 35 years. 
Statistical analysis 
The following continuous ECG interval parameters were summarized for each group 
(normal, moxifloxacin, LQT1 and LQT) and subgroup (sex and algorithm) of interest using 
central tendency analyses: RR, PR, QRS, and QT (not adjusted for rate). Standard summary 
statistics are presented in the tables including the mean and 95% confidence intervals (CI) 
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around the mean.  The difference between algorithms was assessed by the ability of each 
algorithm to perform as expected (i.e., detecting known interval differences between sex and 
between ECG groups), by the intrinsic variability within each algorithm, and by evaluating 
pairwise differences between algorithms.   
To compare the expected means between algorithms, sex and ECG groups, repeated 
measures regression models were used for each interval with ECG serving as the random effect 
and ECG group, sex and algorithm as the fixed effects. We assumed a compound symmetry 
variance structure with equal variances across ECG groups and tested this assumption using 
likelihood ratio tests comparing models utilizing other possible covariance structures. Two-sided 
95% confidence intervals (CI) for the difference between subgroups of interest were constructed 
using the residual error of the regression model and applying the Tukey alpha-adjustment for 
multiple pairwise comparisons.   
Initially, interval and duration measurement differences between algorithms were 
examined in subjects separated by ECG group (normal, moxifloxacin, LQT1, and LQT2).  
Measurement differences were then examined within algorithms in subjects separated by sex. 
Interval data were also examined for differences separated by algorithm and by ECG group; 
these findings were used to examine the significance of differences within each algorithm 
associated with normal, moxifloxacin, LQT1 and LQT2 status.  By considering seven algorithms, 
21 (7 x 6/2) possible unique pairwise comparisons of mean differences between algorithms for 
each ECG measurement (PR, RR, QRS, and QT) could be made overall and within each 
subgroup (sex and ECG group).  In several instances, automated algorithms were not able to 
measure a PR interval, slightly reducing the total number of observations within a given 
subgroup as seen in the tables.  
To examine the effects of normal, moxifloxacin, LQT1 and LQT2 group status on overall 
measurement differences between algorithms, a separate analysis was conducted for each 
ECG interval (RR, PR, QRS, and unadjusted QT) to evaluate the overall mean and variability of 
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all possible pairwise comparisons between algorithms.  For each ECG group of 200 subjects 
(normal, moxifloxacin, LQT1 and LQT2), 4,200 (200 x 21) possible unique paired differences 
between algorithms can be constructed. These differences are represented by boxplots showing 
the median, 25th, and 75th percentiles with superimposed mean and whiskers for denoting 
minimum and maximum values. 
All statistical data analyses were completed using SAS software, Version 9.4 (SAS 
Institute Inc., Cary, NC, USA).  A p-value ≤ 0.05 was considered statistically significant unless 
otherwise noted. 
 
RESULTS 
Measurement differences in total population by algorithm 
Summary statistics for the entire population of 800 subjects by algorithm, not further 
separated by ECG group or sex, are shown in Table 1.  Pairwise differences between each 
mean interval value were clinically small, ranging from 0.0 to 6.9 ms for RR interval, 0.2 to 3.6 
ms for the PR interval, 0.1 to 8.1 ms for QRS duration, and 0.1 to 9.3 ms for unadjusted QT 
interval, but some systematic differences were present. Several of the 21 possible unique 
pairwise differences between means amongst the seven algorithms for each interval 
measurement did reach statistical significance as indicated in the table footnote.   
Interval measurement differences within algorithm in total population separated by sex 
Among the entire population separated by sex but not by ECG group, within each of the 
seven algorithms, the mean RR intervals, PR intervals, and QRS durations were significantly 
longer in men than for women (pairwise Tukey-adjusted p<0.001) for all comparisons with each 
algorithm.  Interestingly, the mean unadjusted QT intervals in this entire population, half of 
whom were patients with genotyped LQT1 and LQT2, were similar for women and for men 
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within each of the seven algorithms (p=ns for all comparisons); mean differences were relatively 
small, ranging from 0.7 to 4.3 ms (Table 2 and Figure 1). It is emphasized that these values are 
unadjusted for heart rates or cycle lengths, with significantly shorter cycle lengths in women. 
The influence of LQT patients on the overall QT differences is further explored by examination 
of group differences below. 
Interval measurement differences within ECG groups by algorithm 
Interval measurement differences according to algorithm within each ECG group, but not 
further separated according to sex, are shown in Table 3 and Figures 2-4.  For the PR interval 
comparisons (Figure 2), there were trends observed for shorter AV conduction time in the LQT 
groups than in the normal and moxifloxacin groups, but statistical significance was reached only 
for LQT1 compared to both normal and moxifloxacin within the AMPS algorithm (p< 0.05) and 
within the GE algorithm (p<0.005).  QRS durations (Figure 3) were significantly shorter in LQT1 
and LQT2 compared to normal and moxifloxacin groups within the GE (p<0.001), Means 
(p<0.001), Mortara (p<0.02), and Schiller (p<0.001) algorithms.  QRS durations were also 
significantly shorter in LQT1 and LQT2 than in normal ECGs for the Glasgow algorithm (p< 
0.02), but did not reach significance for the LQT groups compared with moxifloxacin.  All other 
pairwise QRS differences were not statistically significant. Within algorithms, all differences for 
unadjusted QT interval between ECG groups (Figure 4) were significantly different (p<0.025), 
with progressive QT prolongation from normal to moxifloxacin to LQT1 to LQT2 groups; this 
includes significantly higher unadjusted QT intervals, ranging from 10.3 to 11.8 ms, in the 
moxifloxacin compared with normal subjects at comparable cycle lengths, for all algorithms. 
Within individual groups, pairwise differences of means between algorithms for PR 
interval ranged from 0.2 to 3.6 ms in normal ECGs, 0.3 to 3.3 ms in moxifloxacin, 0.6 to 3.6 ms 
in LQT1, and 0.0 to 4.1 ms in LQT2 groups.  Pairwise mean differences between algorithms for 
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QRS duration ranged from 0.4 to 6.8 ms in normal ECGs, 0.1 to 6.7 ms in moxifloxacin, 0.2 to 
13.3 ms in LQT1, and 0.2 to 11.0 ms in LQT2 groups.  Pairwise mean differences between 
algorithms for unadjusted QT interval ranged from 0.1 to 11.3 ms in normal ECGs, 0.3 to 10.2 
ms in moxifloxacin, 0.2 to 10.5 ms in LQT1, and 0.9 to 12.8 in LQT2 groups.    
Range of interval differences for total paired individual measurements within ECG groups 
Within each of the 4 diagnostic ECG groups (200 subjects per group), 4,200 individual 
paired differences were possible for each of the RR, QRS duration, and QT interval 
measurements between all single ECGs; however, only 4,111 to 4,188 paired differences for PR 
intervals were possible due to unmeasurable PR intervals within a small number of subjects.  
Boxplots of these differences are illustrated in Figure 5, showing the mean, median, 25th and 
75th percentiles, and range.  Note that these findings represent the mean of all differences, 
rather than a difference of means, and therefore these data represent the magnitude of 
variability of measurement between algorithms for the different groups, not the magnitude of the 
underlying measurements. Considerable overlap was observed between ECG groups for each 
interval measurement difference and the range of differences above the 75th percentile was 
large, indicating larger differences for some of the individual comparisons.   
No clinically significant mean individual paired differences for RR intervals between 
groups were found, but some differences did reach statistical significance, particularly in the 
LQT1 and LQT2 groups.  PR interval mean individual paired differences were not significant 
between normal and moxifloxacin groups or separately between LQT1 and LQT2 groups. 
However, despite considerable overlap, mean individual paired differences for PR interval were 
significantly greater for each of the LQT groups than for the normal group and, separately, also 
for the moxifloxacin group (p<0.02).  Mean individual paired differences for QRS duration were 
not significantly different between the normal and the moxifloxacin groups, but the mean 
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individual difference of 7.4 ± 8.5 ms in the LQT1 group was significantly greater than the 6.5 ± 
5.7 ms mean difference in the LQT2 group (p= 0.014, adjusted for multiple comparison). Mean 
individual paired QRS duration was larger in the LQT1 group than in either normal or 
moxifloxacin groups, while mean individual paired QRS difference in the LQT2 group was larger 
than in the normal, but not in the moxifloxacin groups.  Mean individual paired difference for 
unadjusted QT duration was 9.9 ± 15.3 ms for LQT1 and 12.6 ± 17.2 ms for LQT2 (p< 0.001, 
adjusted for multiple comparison), each of which was separately greater than in the normal and 
moxifloxacin groups.   
 
DISCUSSION 
Even though all algorithms separate groups with normal and abnormal QT intervals, 
small but statistically significant group differences in mean interval and duration measurements 
and means of individual absolute differences exist among the seven automated algorithms of 
widely used, current-generation digital electrocardiographs. The overall population differences 
seen in Table 1 are not explained entirely by data from the abnormal LQT groups, since smaller 
differences also are seen within the normal and moxifloxacin groups.  While the magnitudes of 
these differences are unlikely to be clinically significant for any single measurement comparison, 
systematic differences can have consequences for outcomes when different algorithms are 
used during the course of longitudinal evaluations such as thorough QT studies,.4, 5, 7 in 
comparative studies of normal values and risk prediction in different populations,9, 10, 16, 17 and for 
the establishment of normal limits in routine electrocardiography.18  For such research 
purposes, attention must be paid to methodologic consistency in the comparison of measured 
values, particularly for measurements of QRS duration and for QT interval.  
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It is well recognized that, in general populations, women have systematically shorter RR 
intervals, PR intervals, and QRS durations, but longer heart rate adjusted QT intervals, than 
men.18-20  Although there are known changes in intervals with age, mean ages are similar for all 
groups in this study.  Differences between sex were found by all algorithms for RR, PR and 
QRS intervals.  However, as seen in Figure 1 and Table 2, overall sex related differences in 
unadjusted QT interval are not statistically significantly different in the present analysis. This 
finding is a consequence of comparison of QT intervals that are not heart rate corrected for the 
purpose of this study.  It can be estimated from the significantly different cycle lengths in men 
and in women that rate adjustment by any of the standard formulae would result in longer QT 
values for women than for men in this population.  The effect of a 50% admixture of long QT 
subjects in the total population, half LQT1 and half LQT2, on mean QT values in men and 
women is uncertain and requires further study.14, 15  As seen in Figure 2, other differences 
between groups within each algorithm include trends toward shorter PR intervals, shorter QRS 
durations, and significantly longer QT intervals in the LQT subjects, with longer QT in LQT2 than 
in LQT1 groups. These findings also require further sub-analyses within the LQT groups 
themselves, with heart rate adjustment, that are beyond the scope of the present report. 
Our current findings support the hypothesis that the magnitude of difference between 
measurements by different automated algorithms increases with the degree of abnormality of 
the underlying ECGs.3, 6  Computer-based ECGs measure intervals on differently implemented 
“global” as opposed to single lead basis, which increases measurement precision and 
reproducibility within algorithms and should remove uncertainty regarding waveform onset and 
offset obtained in any individual lead.1, 21  But even so, the lack of a formal medical definition of 
the end of the QRS complex and the end of the T wave leaves the concept of “global” intervals 
subject to individual engineering solutions by different algorithm developers.4  Since these 
solutions vary, as noted in the appendix, different results might be expected for automated 
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measurement of the QRS and QT intervals, and perhaps also for PR intervals which are 
dependent on the detection of smaller, low frequency waveforms.  Thus, for example, it is well 
recognized that T wave offset measurement is highly dependent on T wave amplitude and 
shape, and separately confounded by isoelectric projection of rounded T wave loops that are 
more common in abnormal subjects than in normals.22-29  Interestingly, despite longer QT 
intervals apparent in the moxifloxacin vs normal subject groups (Figure 4), differences between 
automated algorithms remained comparably small in these two groups (Figure 5).  These 
findings are consistent with the relative preservation of T wave shape and amplitude in subjects 
receiving moxifloxacin in contrast with other types of QT prolonging drugs.30  
Of note, two of the original 4 algorithms were modified in response to (or following) the 
original comparison study published in 2014.  There seems to have been some harmonization 
of QT interval measurement as a result: among the 4 original comparisons, the longest mean 
QT difference between algorithm pairs in the long QT population (then comprising mixed LQT1 
and LQT2 subjecgts) was 18 ms.  In the present study of 7 algorithms, which include the original 
4 algorithms with some methodoligic modification, the maximum mean QT interval difference 
was only 10 ms for the LQT1 patients and 12 ms for the LQT2 patients.  Since this represents 
an overall trend within which the original algorithms are included, it argues for improvement in 
differences in QT measurment compared with the original study. 
Abnormal notching, symmetry, and low amplitude are features of abnormal ECGs in our 
LQT subjects,31-34 which are also found in many forms of established heart disease and in other 
acquired channelopathies.23, 35, 36  This complicates the identification and measurement of the T 
wave in subjects with abnormal ECGs.  When the T wave is abnormal, therefore, different 
engineered solutions for recognition of the end of the T wave would be expected to result in the 
most QT variation between algorithms, as noted here (Figure 5) and also in our prior report.3 
Other differences between ECG waveforms, based on ion channel variations, structural 
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disease, or drug effect might similarly affect QRS measurement differences between study 
groups as well as in other populations. It is therefore of interest to note the increased variability 
among algorithms for the measurement of QRS duration in our long QT subjects compared with 
normals and subjects taking moxifloxacin, a finding also noted in our prior report.3  The 
mechanisms affecting QRS fiducial waveform point ascertainment in LQT1 and LQT2 
accordingly require specific investigation.  
The major purpose of this cooperative trial was to establish whether systematic 
differences in measurement among these widely used algorithms might have consequences for 
clinical and epidemiological research, and if so, how these differences relate to the extent of 
ECG abnormality. Weighted averaging of expert cardiologist opinions has been used for 
comparison of computer diagnosis of standard ECG statements such as ventricular hypertrophy 
and myocardial infarction in the CSE database (European Working Party on Common 
Standards for Quantitative Electrocardiography).37 By design, there was no attempt to establish 
a physician-adjudicated “gold standard” for the automated interval measurements examined in 
this study. There is one major reason and a subsidiary rationalization for this decision.  Most 
important, the suggestion that one proprietary engineering solution to ECG interval 
measurement is more “correct” than another would have introduced a competitive commercial 
aspect to participation.  Absence of imputed relative performance was essential to 
accomplishing this cooperative study; under the present conditions, any of the tested algorithms 
might be closest to an undetermined “truth,” if there is one.  But separately, in the absence of 
absolute medical definition of waveform fiducial points, the stability of any human adjudicated 
“gold standard” for interval measurements is itself subject to uncertainty. Expert ECG over-
readers, like algorithms, also vary in interval determinations, perhaps in part based on 
cumulative experience with manual and semi-automated adjudication using different single-lead 
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and global methodologies.5, 7, 38-40  This makes absolute acceptance of any collective “gold 
standard” arguable, even when quantifiable.  
In summary, systematic differences among ECG interval measurements by current, 
widely-used computer-based algorithms are small. Even so, comparisons of ECG population 
norms should be aware of potential differences in interval measurements that might result from 
different algorithm methodologies. In addition, within-individual interval measurement 
comparisons with clinical implications should use comparable methods, and further attempts to 
harmonize interval measurement methodologies among algorithms are warranted. 
 
 
 
  
17 
 
REFERENCES 
1. Kligfield P, Gettes LS, Bailey JJ, Childers R, Deal BJ, Hancock EW, van Herpen G, Kors 
JA, Macfarlane P, Mirvis DM, Pahlm O, Rautaharju P, Wagner GS, Josephson M, 
Mason JW, Okin P, Surawicz B, Wellens H. Recommendations for the standardization 
and interpretation of the electrocardiogram: Part i: The electrocardiogram and its 
technology: A scientific statement from the American Heart Association 
Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the 
American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed 
by the International Society for Computerized Electrocardiology. Circulation 
2007;115:1306-1324. 
2. Garg A, Lehmann MH. Prolonged QT interval diagnosis suppression by a widely used 
computerized ECG analysis system. Circulation: Arrhythmia and Electrophysiology 
2013;6:76-83. 
3. Kligfield P, Badilini F, Rowlandson I, Xue J, Clark E, Devine B, Macfarlane P, de Bie J, 
Mortara D, Babaeizadeh S, Gregg R, Helfenbein ED, Green CL. Comparison of 
automated measurements of electrocardiographic intervals and durations by computer-
based algorithms of digital electrocardiographs. Am Heart J 2014;167:150-159. 
4. Kligfield P, Hancock EW, Helfenbein ED, Dawson EJ, Cook MA, Lindauer JM, Zhou SH, 
Xue J. Relation of QT interval measurements to evolving automated algorithms from 
different manufacturers of electrocardiographs. The American Journal of Cardiology 
2006;98:88-92. 
5. Hnatkova K, Gang Y, Batchvarov VN, Malik M. Precision of QT interval measurement by 
advanced electrocardiographic equipment. Pacing and Clinical Electrophysiol: PACE 
2006;29:1277-1284. 
18 
 
6. Tyl B, Azzam S, Blanco N, Wheeler W. Improvement and limitation of the reliability of 
automated QT measurement by recent algorithms. J Electrocardiol 2011;44:320-325. 
7. Azie NE, Adams G, Darpo B, Francom SF, Polasek EC, Wisser JM, Fleishaker JC. 
Comparing methods of measurement for detecting drug-induced changes in the QT 
interval: Implications for thoroughly conducted ECG studies. Ann Noninvasive 
Electrocardiol 2004;9:166-174. 
8. Couderc JP, Garnett C, Li M, Handzel R, McNitt S, Xia X, Polonsky S, Zareba W. Highly 
automated QT measurement techniques in 7 thorough QT studies implemented under 
ich e14 guidelines. Ann Noninvasive Electrocardiol 2011;16:13-24. 
9. Robbins J, Nelson JC, Rautaharju PM, Gottdiener JS. The association between the 
length of the QT interval and mortality in the cardiovascular health study. Am J Med 
2003;115:689-694. 
10. Dekker JM, Crow RS, Hannan PJ, Schouten EG, Folsom AR. Heart rate-corrected QT 
interval prolongation predicts risk of coronary heart disease in black and white middle-
aged men and women: The aric study. J Am Coll Cardiol 2004;43:565-571. 
11. de Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, Grobbee DE. Prolonged 
QT interval predicts cardiac and all-cause mortality in the elderly. The rotterdam study. 
Eur Heart J 1999;20:278-284. 
12. Kligfield P, Green CL, Mortara J, Sager P, Stockbridge N, Li M, Zhang J, George S, 
Rodriguez I, Bloomfield D, Krucoff MW. The cardiac safety research consortium 
electrocardiogram warehouse: Thorough qt database specifications and principles of use 
for algorithm development and testing. Am Heart J 2010;160:1023-1028. 
13. Kligfield P, Green CL. The Cardiac Safety Research Consortium ECG database. J 
Electrocardiol 2012;45:690-692. 
19 
 
14. Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, Chivoret G, 
Schwartz K, Coumel P, Guicheney P. KVLQT1 c-terminal missense mutation causes a 
forme fruste long-QT syndrome. Circulation 1997;96:2778-2781. 
15. Dausse E, Berthet M, Denjoy I, Andre-Fouet X, Cruaud C, Bennaceur M, Faure S, 
Coumel P, Schwartz K, Guicheney P. A mutation in herg associated with notched t 
waves in long QT syndrome. J Mol Cell Card 1996;28:1609-1615. 
16. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Jern S, Dahlof B, Devereux RB, 
Okin PM. Qrs duration and QT interval predict mortality in hypertensive patients with left 
ventricular hypertrophy: The losartan intervention for endpoint reduction in hypertension 
study. Hypertension 2004;43:1029-1034. 
17. Porthan K, Viitasalo M, Jula A, Reunanen A, Rapola J, Vaananen H, Nieminen MS, 
Toivonen L, Salomaa V, Oikarinen L. Predictive value of electrocardiographic QT interval 
and t-wave morphology parameters for all-cause and cardiovascular mortality in a 
general population sample. Heart Rhythm 2009;6:1202-1208. 
18. Macfarlane PM, Chen CY, Chiang BN. Comparison of the ECG in apparently healthy 
chinese and caucasians. IEEE Computers in Cardiology 1988:143-146. 
19. Macfarlane PW, McLaughlin SC, Devine B, Yang TF. Effects of age, sex, and race on 
ECG interval measurements. J Electrocardiol 1994;27: Suppl:14-19. 
20. Mandic S, Fonda H, Dewey F, Le VV, Stein R, Wheeler M, Ashley EA, Myers J, 
Froelicher VF. Effect of gender on computerized electrocardiogram measurements in 
college athletes. Phys Sportsmed 2010;38:156-164. 
21. Kligfield P, Tyl B, Maarek M, Maison-Blanche P. Magnitude, mechanism, and 
reproducibility of QT interval differences between superimposed global and individual 
lead ECG complexes. Ann Noninvasive Electrocardiol 2007;12:145-152. 
22. Batchvarov V, Malik M. Measurement and interpretation of QT dispersion. Prog 
Cardiovasc Dis 2000;42:325-344. 
20 
 
23. Couderc JP, Zareba W, Moss AJ, Sarapa N, Morganroth J, Darpo B. Identification of 
sotalol-induced changes in repolarization with t wave area-based repolarization duration 
parameters. J Electrocardiol. 2003;36: Suppl:115-120. 
24. Kautzner J. QT interval measurements. Card Electrophysiol Rev 2002;6:273-277. 
25. Kligfield P, Okin PM, Lee KW, Dower GE. Significance of QT dispersion. Am J Cardiol 
2003;91:1291. 
26. Kors JA, van Herpen G. Measurement error as a source of qt dispersion: A 
computerised analysis. Heart 1998;80:453-458. 
27. Lee KW, Kligfield P, Dower GE, Okin PM. QT dispersion, t-wave projection, and 
heterogeneity of repolarization in patients with coronary artery disease. Am J Cardiol 
2001;87:148-151. 
28. McLaughlin NB, Campbell RWF, Murray A. Influence of t wave amplitude on automatic 
QT measurement. IEEE Computers in Cardiology 1995:777-780. 
29. Andersen MP, Xue JQ, Graff C, Kanters JK, Toft E, Struijk JJ. New descriptors of t-wave 
morphology are independent of heart rate. J Electrocardiol 2008;41:557-561. 
30. Couderc JP, Vaglio M, Xia X, McNitt S, Wicker P, Sarapa N, Moss AJ, Zareba W. 
Impaired t-amplitude adaptation to heart rate characterizes I(Kr) inhibition in the 
congenital and acquired forms of the long QT syndrome. J Cardiovasc Electrophysiol 
2007;18:1299-1305. 
31. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin 
JA, Vincent GM, Lehmann MH. ECG T-wave patterns in genetically distinct forms of the 
hereditary long QT syndrome. Circulation 1995;92:2929-2934. 
32. Zareba W, Moss AJ, Konecki J. Tu wave area-derived measures of repolarization 
dispersion in the long QT syndrome. J Electrocardiol 1998;30: Suppl:191-195. 
33. Zhang L, Timothy KW, Vincent GM, Lehmann MH, Fox J, Giuli LC, Shen J, Splawski I, 
Priori SG, Compton SJ, Yanowitz F, Benhorin J, Moss AJ, Schwartz PJ, Robinson JL, 
21 
 
Wang Q, Zareba W, Keating MT, Towbin JA, Napolitano C, Medina A. Spectrum of ST-T 
wave patterns and repolarization parameters in congenital long-QT syndrome: ECG 
findings identify genotypes. Circulation. 2000;102:2849-2855 
34. Zareba W. Genotype-specific ECG patterns in long QT syndrome. Journal of 
Electrocardiol 2006;39:S101-106. 
35. Chiang CE. Congenital and acquired long QT syndrome. Current concepts and 
management. Cardiol Rev. 2004;12:222-234. 
36. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, 
Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: A scientific 
statement from the American Heart Association and the American College of Cardiology 
Foundation. Circulation 2010;121:1047-1060. 
37. Willems JL, Abreu-Lima C, Arnaud P, van Bemmel JH, Brohet C, Degani R, Denis B, 
Gehring J, Graham I, van Herpen G, et al. The diagnostic performance of computer 
programs for the interpretation of electrocardiograms. N Engl J Med 1991;325:1767-
1773. 
38. Darpo B, Agin M, Kazierad DJ, Layton G, Muirhead G, Gray P, Jorkasky DK. Man 
versus machine: Is there an optimal method for QT measurements in thorough QT 
studies? J Clin Pharm 2006;46:598-612 
39. Hnatkova K, Malik M. Automatic adjustment of manually measured QT intervals in digital 
electrocardiograms improves precision of electrocardiographic drug studies. IEEE 
Computers in Cardiology 2002:697-700. 
40. Malik M. Errors and misconceptions in ECG measurement used for the detection of drug 
induced QT interval prolongation. J Electrocardiol 2004;37 Suppl:25-33. 
  
22 
 
APPENDIX: Methodologic Statements by Participating Algorithms: 
 
AMPS: Fiducial Point Detection 
The BRAVO algorithm provides automated measurements from the 10 second raw ECG 
data and also from mathematically derived single-beat representative waveforms (averaged or 
median beats). In the latter case, measurements can be performed from each individual lead or, 
as in this study, from a “global” lead computed as the vector magnitude of the independently 
acquired leads. On the global lead, the QRS onset and offset detection points are based on the 
resampled (1000 Hz) and normalized waveform and on the combined implementation of an 
adaptive threshold moving average and of a high-pass regressive filter. The QRS onset is 
searched starting from the R-peak position going backward, identifying the right-edge of an 
interval of contiguous samples with minimal variability. Similarly, the QRS offset detection point 
is assigned on the high-pass filtered signal as the left-edge of a 5 millisecond interval which is 
constantly below a threshold that is iteratively increased until the condition is met. Lower 
frequency segments (P- and T-waves) are then analyzed by a series of signal processing steps 
that include non-distorting low-pass filtering (bidirectional 4th order Butterworth) and first and 
second derivative analyses. P onset and T wave offset markers are defined as the backward or 
forward sample points where the first derivative of the signal goes below a fixed percent of the 
maximum value (reached at the maximum ascending or descending slope of each wave). 
 
GE Healthcare 
In the GE Healthcare 12SL ECG Analysis Program, all intervals and measurements are 
made from the median complex.  The median complex is the representative 12-lead complex 
formed by time-aligning all beats of the dominant morphology and using a proprietary nonlinear 
type of signal averaging.  After the median complex is formed, the onsets and offsets are 
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determined in the following order: QRS onset, QRS offset, T offset, P onset, and P offset.  
Immediately after the T offset is determined, the median complex is searched for a synchronous 
P wave.  The P onset and offset are determined only if a P wave is found.  The exact method for 
identifying each onset and offset is tuned for each of the markers, but all use variations of the 
same approach.  The fundamental detection function for each marker search is a “superlead”, 
which is the sum of the absolute value of all independent leads (I, II, V1, … V6).  In some cases, 
the first or second derivatives of the superlead are calculated, and in other cases, the 
derivatives are calculated first and then summed to form the superlead.  Such detection 
functions accentuate the slope changes that accompany a wave onset or offset.  After the onset 
and offset points are found, the intervals are calculated from the time differences between the 
appropriate markers. See Xue J, QT Interval Measurement: What Can We Really Expect? 
Computers in Cardiology 2006;33:385−388. 
 
Glasgow Program 
Based on the availability of an average beat, different approaches to finding fiducial 
points have been tried, including a simple form of threshold crossing to a more complex 
template matching technique. Ultimately, a combination of these approaches has been adopted 
where, for example, QRS onset was found to perform best with respect to a noisy test set using 
a threshold technique. On the other hand, T-end performed best using a template matching 
method. All QRST amplitudes are referred to QRS onset, as are P wave measurements.  
Individual QRS and T wave fiducial points are derived for all leads and a method of selecting the 
earliest QRS onset for example is utilized in order to determine a global QRS onset. A similar 
approach is adopted for QRS termination and the difference between the two global 
measurements is taken as the overall QRS duration. It was found optimum to utilize a common 
P onset and P termination in view of the unreliability of P wave detection in many ECGs. 
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MEANS Program, Erasmus University Medical Center, Rotterdam, The Netherlands 
The Modular ECG Analysis System (MEANS) locates the QRS complexes using the 
spatial velocity, which is computed from the reconstructed vectorcardiographic X, Y, and Z 
leads. The QRS complexes are typed as dominant and non-dominant, and a representative P-
QRS-T complex per lead is obtained by averaging the time-aligned dominant complexes. 
Complexes affected by sudden baseline shifts or other major disturbances are excluded from 
averaging. MEANS determines common inflectional points (P onset, P offset, QRS onset, QRS 
offset, T offset) for all 12 leads together. The spatial velocity derived from the representative 
complexes is used as the detection function. For determination of QRS onset and offset, the 
detection function is matched with a template. The template matching method takes into 
account information on the time-amplitude distribution of the detection function in a window 
around the inflectional point. For T offset, the template is heart-rate dependent, to take care of 
the P-on-T phenomenon that may occur at higher heart rates. When the template match is not 
good enough, MEANS enters a thresholding algorithm to locate the minimum of the spatial 
velocity, which is then taken as the end of the T wave. For determination of P onset and offset, 
MEANS uses thresholding algorithms. PR interval, QRS duration, and QT interval are calculated 
from the time differences between the pertinent fiducial points. 
 
Mortara Instrument: 
All ECG landmarks, P onset/offset, QRS onset/offset, and T offset, are global, with a 
single index spanning all leads for each landmark. The detection of these landmarks is generally 
done using a spatial velocity magnitude, defined as the absolute differences of neighboring 
samples, summed over the available leads. The first step in landmark detection is the formation 
of a representative cardiac cycle from the cycles labeled as part of the dominant rhythm. 
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Premature beats, even with QRS morphologies similar to the dominant rhythm, are excluded to 
avoid influencing P wave and repolarization details. The representative cycle is referred to as a 
median, although the actual process is a median of 3 averages, with the 3 averages found from 
modulo 3 normal beat cycles (that is, average 1 of beat 1, 4, 7, 10…, average 2 of beat 2, 5, 8, 
11…, average 3 of beat 3, 6, 9, 12 …). The representative cycle is recursively low pass filtered 
until the high-frequency noise is brought below a threshold, with the aim of robust landmark 
detection in the presence of noise. P-wave landmark detection first requires locating the peak 
spatial magnitude of a high pass filter applied to the T-P segment. Onset and offset are 
determined by fitting straight lines to 16-ms linear segments and locating the boundaries where 
the straight line fit improves (decreases) below a threshold. This straight line model allows P 
onset/offset to be properly located even when the P is superimposed on the terminal part of a T 
wave. QRS landmarks use a similar straight line fit to refine the details of onset/offset. Initially, 
spatial velocities are used to crudely locate estimates of the onset and offset. The straight line 
tests again work well in cases of steeply sloped PR/ST segments. T wave offset detection 
poses special problems because there is no precise end of repolarization. To avoid too 
early/late offset marking in cases of low/high amplitude T waves, the offset slope threshold is 
scaled to the amplitude of the largest T wave in any lead.  (It can be noted in Table 1 and Table 
2 that the average RR-interval measured by the Mortara VERITAS program is approximately 6 
ms shorter than the average of the other programs. This shorter RR-interval is not real and an 
artifact of the measurement methodology used in this particular study; it does not represent a 
difference that is present in actual Mortara products.)           
 
Philips Healthcare 
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The Philips DXL algorithm measures each lead first and then determines the global PR 
interval, QRS duration and QT interval from the set of fiducial points on each lead. The process 
starts with detecting QRS and then segmenting into P, QRS and T on an activity or envelope 
function which is a weighted sum of first and second differences. Next, beats are compared and 
classified as normal or ectopic with the normal beats making up the representative averaged 
beat. Each lead of the average beat is measured based on deflections characterized by maxima 
and zero crossings of smoothed first and second differences. The end of the T-wave is 
estimated from the maximum distance between the signal and a secant line drawn from the 
peak of the T-wave out a fixed time duration to a point beyond the end of the T-wave. The end 
of the QRS is measured with a similar secant line from the last S or R-wave into the T-wave. 
The final global PR interval, QRS duration and QT interval comes from the earliest onset and 
the last end point across leads with logic to prevent choosing an outlier or a value from a noisy 
lead. 
 
Schiller AG: 
 Global ECG Measurement: A QRS detector determines the positions of all heart beats 
within a given ECG signal. These positions are the basis for the calculation of the average RR 
interval. All detected heart beats are assigned to one or several beat classes based on their 
morphological similarity. The morphological similarity is determined by cross-correlation 
calculations in the range of the QRS complexes. The beat class that contains the largest 
number of beats with the shortest QRS duration corresponds to the predominant normal beat 
class. The heart beats that are assigned to this predominant normal beat class are used for the 
average beat construction. They are first time-aligned by means of cross-correlation and then 
averaged by calculating a robust mean value sample by sample. Based on derived 
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vectorcardiographic leads X, Y and Z and their time derivatives dX, dY and dZ, the absolute 
spatial velocity ASV = sqrt(dX*dX + dY*dY + dZ*dZ) is calculated. The ASV of the average beat 
is used to determine the global time marker positions (P-wave onset/offset, QRS complex 
onset/offset and T-wave offset). These markers are placed at the positions where the ASV gets 
to a stable minimum before/after the P wave, before/after the QRS complex and after the T 
wave. The PR interval, QRS duration and QT interval are the time differences between pairs of 
these global markers. 
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Table 1: Mean Intervals by Algorithm in Total Population 
Interval n Algorithm Mean ±SD 
(ms) 
Lower 95% 
CI (ms) 
 
Upper 95% 
CI (ms) 
 
RR* 800 AMPS 979 ± 180 966 991 
 800 GE 978 ± 180 966 991 
 800 Glasgow 978 ± 180 966 991 
 800 Means 979 ± 182 966 992 
 800 Mortara 973 ± 179 960 985 
 800 Philips 980 ± 180 967 992 
 800 Schiller 979 ± 182 966 992 
      
PR** 800 AMPS 155 ± 22 154 157 
 800 GE 154 ± 21 152 155 
 798 Glasgow 152 ± 22 150 154 
 789 Means 156 ± 21 154 157 
 785 Mortara 153 ± 23 152 155 
 799 Philips 154 ± 22 152 155 
 796 Schiller 154 ± 23 152 155 
      
QRS*** 800 AMPS 89 ± 10 89 90 
 800 GE 85 ± 12 84 86 
 800 Glasgow 89 ± 11 88 90 
 800 Means 92 ± 13 91 93 
 800 Mortara 92 ± 11 91 93 
 800 Philips 93 ± 12 92 94 
29 
 
 800 Schiller 90 ± 12 89 90 
      
QT**** 800 AMPS 423 ± 47 420 427 
 800 GE 429 ± 45 426 432 
 800 Glasgow 433 ± 44 430 436 
 800 Means 430 ± 43 427 433 
 800 Mortara 423 ± 43 420 426 
 800 Philips 432 ± 45 429 435 
 800 Schiller 428 ± 43 425 431 
*p=ns by Tukey-adjusted repeated measures analysis of variance for comparisons of RR 
between algorithms, except p<0.001 for AMPS vs Mortara; GE vs Mortara and Philips; Glasgow 
vs Mortara and Philips; Means vs Mortara; and Mortara vs Philips and Schiller. **p<0.001 for all 
comparisons of PR between algorithms except non-significant for AMPS vs Means; GE vs 
Mortara, Philips and Schiller; Mortara vs Philips and Schiller; and Philips vs Schiller.  ***p<0.02 
for all comparisons of QRS duration between algorithms except non-significant for AMPS vs 
Glasgow and Schiller; Glasgow vs Schiller; and Means vs Mortara.  ****Note that QT 
measurements are not rate corrected; p<0.03 for all comparisons of unadjusted QT between 
algorithms except non-signficant for AMPS vs Mortara; GE vs Means and Schiller; and Glasgow 
vs Philips.  
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Table 2: Mean Intervals, by Sex and Algorithm 
Interval Sex N Algorithm Mean ± SD 
(ms) 
Lower 95% 
CI (ms) 
 
Upper 95% 
CI (ms) 
 
RR* Men 377 AMPS 1026 ± 181 1008 1044 
  377 GE 1026 ± 181 1008 1044 
  377 Glasgow 1026 ± 181 1008 1043 
  377 Means 1026 ± 183 1008 1044 
  377 Mortara 1021 ± 180 1004 1039 
  377 Philips 1027 ± 181 1009 1045 
  377 Schiller 1027 ± 182 1009 1044 
 Women 423 AMPS 937 ± 170 920 953 
  423 GE 935 ± 168 919 952 
  423 Glasgow 936 ± 168 919 952 
  423 Means 937 ± 171 920 953 
  423 Mortara 929 ± 166 913 946 
  423 Philips 937 ± 169 921 954 
  423 Schiller 937 ± 171 920 953 
       
PR** Men 377 AMPS 159 ± 23 157 161 
  377 GE 157 ± 22 155 159 
  377 Glasgow 155 ± 23 153 157 
  370 Means 160 ± 22 158 162 
  369 Mortara 157 ± 24 155 159 
  377 Philips 157 ± 24 155 159 
  376 Schiller 157 ± 24 155 159 
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 Women 423 AMPS 152 ± 21 150 154 
  423 GE 151 ± 20 149 153 
  421 Glasgow 149 ± 21 147 152 
  419 Means 153 ± 20 151 155 
  416 Mortara 150 ± 21 148 153 
  422 Philips 151 ± 21 149 153 
  420 Schiller 151 ± 22 148 153 
       
QRS*** Men 377 AMPS 92 ± 12 91 93 
  377 GE 90 ± 12 89 91 
  377 Glasgow 93 ± 12 92 94 
  377 Means 96 ± 15 95 98 
  377 Mortara 96 ± 12 95 97 
  377 Philips 95 ± 13 94 97 
  377 Schiller 94 ± 12 93 95 
 Women 423 AMPS 87 ± 9 86 88 
  423 GE 80 ± 9 79 81 
  423 Glasgow 85 ± 8 84 86 
  423 Means 88 ± 10 86 89 
  423 Mortara 88 ± 8 87 89 
  423 Philips 91 ± 11 89 92 
  423 Schiller 86 ± 12 84 87 
Interval Sex n Algorithm Mean ± SD 
(ms) 
Lower 95% 
CI (ms) 
 
Upper 95% 
CI (ms) 
 
QT**** Men 377 AMPS 421 ± 47 416 426 
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  377 GE 428 ± 44 423 432 
  377 Glasgow 431 ± 44 427 436 
  377 Means 429 ± 43 424 433 
  377 Mortara 423 ± 44 418 427 
  377 Philips 432 ± 45 427 437 
  377 Schiller 429 ± 42 424 433 
 Women 423 AMPS 425 ± 46 421 430 
  423 GE 431 ± 45 427 435 
  423 Glasgow 434 ± 45 430 438 
  423 Means 431 ± 44 427 435 
  423 Mortara 424 ± 43 420 428 
  423 Philips 431 ± 45 427 436 
  423 Schiller 427 ± 44 423 432 
*p<0.001 by Tukey-adjusted repeated measures analysis of variance for all comparisons of RR 
between sex within algorithm; **p<0.001 for all comparisons of PR between sex within 
algorithm; ***p< 0.001 for all comparisons of QRS duration between sex within algorithm; 
****p=ns for all comparisons of rate-unadjusted QT between sex within algorithm (including 
groups with LQT1 and LQT2).   
  
33 
 
Table 3: Mean Intervals, by Algorithm and Group, for PR, QRS, and QT Intervals 
 
Interval Algorithm n Group Mean ±SD 
(ms) 
Lower 95% CI 
(ms) 
 
Upper 95% CI 
(ms) 
 
PR AMPS 200 Normal 157 ± 19 155 161 
  200 Moxifloxacin 157 ± 18 154 160 
  200 LQT1 152 ± 22 149 155 
  200 LQT2 154 ± 27 151 157 
 GE 200 Normal 157 ± 19 154 160 
  200 Moxifloxacin 156 ± 17 153 159 
  200 LQT1 149 ± 21 146 152 
  200 LQT2 152 ± 26 149 155 
 Glasgow 200 Normal 154 ± 20 151 157 
  200 Moxifloxacin 154 ± 18 151 157 
  199 LQT1 149 ± 24 146 152 
  199 LQT2 151 ± 27 148 154 
 Means 199 Normal 157 ± 19 154 160 
  200 Moxifloxacin 157 ± 17 154 160 
  195 LQT1 153 ± 22 150 156 
  195 LQT2 156 ± 27 153 159 
 Mortara 198 Normal 156 ± 20 152 159 
  198 Moxifloxacin 155 ± 18 152 158 
  195 LQT1 150 ± 23 147 153 
  194 LQT2 153 ± 29 150 156 
 Philips 200 Normal 155 ± 19 152 158 
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  200 Moxifloxacin 155 ± 19 152 158 
  199 LQT1 151 ± 22 148 154 
  200 LQT2 154 ± 28 151 157 
 Schiller 199 Normal 155 ± 19 152 158 
  200 Moxifloxacin 156 ± 18 152 159 
  200 LQT1 151 ± 23 148 154 
  197 LQT2 153 ± 29 150 157 
       
QRS AMPS 200 Normal 91 ± 8  89 92 
  200 Moxifloxacin 89 ± 8 87 90 
  200 LQT1 89 ± 11 88 91 
  200 LQT2 89 ± 14 87 90 
 GE 200 Normal 89 ± 10  88 91 
  200 Moxifloxacin 88 ± 9 86 89 
  200 LQT1 80 ± 11 79 82 
  200 LQT2 81 ± 14 80 83 
 Glasgow 200 Normal 91 ± 9  88 91 
  200 Moxifloxacin 89 ± 9 88 91 
  200 LQT1 87 ± 11 86 89 
  200 LQT2 88 ± 14 86 89 
 Means 200 Normal 96 ± 10  95 98 
  200 Moxifloxacin 95 ± 10 93 96 
  200 LQT1 87 ± 12 85 89 
  200 LQT2 89 ± 17 87 90 
 Mortara 200 Normal 94 ± 9  93 96 
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  200 Moxifloxacin 94 ± 8 92 95 
  200 LQT1 89 ± 11 88 91 
  200 LQT2 90 ± 14 89 92 
 Philips 200 Normal 93 ± 10  92 95 
  200 Moxifloxacin 92 ± 9 90 94 
  200 LQT1 94 ± 13 92 95 
  200 LQT2 92 ± 15 91 94 
 Schiller 200 Normal 94 ± 10  92 95 
  200 Moxifloxacin 92 ± 9 91 94 
  200 LQT1 86 ± 14 84 87 
  200 LQT2 86 ± 13 85 88 
       
QT* AMPS 200 Normal 397 ± 27 391 402 
  200 Moxifloxacin 408 ± 27 403 414 
  200 LQT1 434 ± 54 429 440 
  200 LQT2 454 ± 48 449 460 
 GE 200 Normal 403 ± 26 398 409 
  200 Moxifloxacin 415 ± 27 409 420 
  200 LQT1 442 ± 53 347 448 
  200 LQT2 457 ± 44 451 462 
 Glasgow 200 Normal 408 ± 26 402 413 
  200 Moxifloxacin 419 ± 27 413 424 
  200 LQT1 444 ± 54 438 439 
  200 LQT2 460 ± 43 455 466 
 Means 200 Normal 408 ± 27 402 413 
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  200 Moxifloxacin 418 ± 28 413 424 
  200 LQT1 441 ± 52 435 446 
  200 LQT2 453 ± 45 448 459 
 Mortara 200 Normal 400 ± 26 395 406 
  200 Moxifloxacin 412 ± 27 406 417 
  200 LQT1 433 ± 54 428 439 
  200 LQT2 448 ± 44 442 453 
 Philips 200 Normal 406 ± 26 400 412 
  200 Moxifloxacin 418 ± 27 412 423 
  200 LQT1 444 ± 55 438 449 
  200 LQT2 459 ± 45 453 464 
 Schiller 200 Normal 406 ± 27 401 412 
  200 Moxifloxacin 417 ± 27 412 423 
  200 LQT1 438 ± 54 432 443 
  200 LQT2 451 ± 42 445 456 
 
* QT intervals are unadjusted for cycle length 
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Legends for Figures 
 
Figure 1.  Mean differences (with 95% confidence intervals) between men and women, by 
algorithm, for automated measurements of (A) RR interval, (B) PR interval, (C) QRS duration, 
and (D) QT interval in the total population of 800 subjects.  Expected sex-dependent differences 
for RR intervals, PR intervals, and QRS durations are clear, while similar unadjusted QT interval 
values are most likely explained by different RR intervals between men and women (see 
discussion). 
Figure 2.  Mean differences (with 95% confidence intervals) in PR intervals between normal, 
moxifloxacin, LQT1, and LQT2 groups, by algorithm.  Note trends toward shorter PR intervals in 
the LQT groups. 
Figure 3.  Mean differences (with 95% confidence intervals) in QRS durations between normal, 
moxifloxacin, LQT1, and LQT2 groups, by algorithm.  Note trends toward shorter QRS durations 
compared with normal and moxifloxacin subjects in some, but not all algorithms. 
Figure 4.  Mean differences (with 95% confidence intervals) in QT intervals between normal, 
moxifloxacin, LQT1, and LQT2 groups, by algorithm.  There is progressive increase in QT for all 
algorithms from normal to moxifloxacin to LQT1 to LQT2 groups.   
Figure 5.  Boxplots with median, 25 and 75% range, and superimposed mean values 
(diamonds) for all possible two-way comparisons of differences between seven algorithms in RR 
intervals, PR intervals, QRS durations, and QT intervals, according to study group.  Both 
median differences and mean differences for PR, QRS, and QT are greater within the LQT1 and 
LQT2 groups than within the normal and moxifloxacin groups, suggesting that differences 
between algorithms are greater in the most abnormal ECGs.  
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